CD8A and respiratory tract infectious disorder: Based on the fact that mucosal vaccines for respiratory infections remain few and far between, identification of novel agents to offer nonmucosal vaccines tailored to the needs of mounting potent respiratory mucosal immunity, especially lung CD8+ Trm, is highly desirable.